University of Queensland researchers are addressing the inadequacies of current methods for treating patients suffering from diabetic neuropathic pain.  Morphine is the "gold standard" analgesic for moderate to severe nociceptive pain. However, opoids are ineffective in the treatment of neuropathic pain.

Enogsia is concerned with four separate patent families that could translate the analgesic benefits of nitric oxide (NO) for the treatment of neuropathic pain - either alone or in combination with an opoid such as morphine.  Involving co-formulation of NO-donors has demonstrated effective analgesia in a widely utilised rat model of neuropathic pain.

Enogsia has the potential to reduce the dose of opoid required to produce analgesia, and offers a means of utilising otherwise ineffective opoid formulations to treat neuropathic pain.  It offers a non-anticonvulsant and non-antidepressant approach.

• Investment
• Licensing